Clinical trial
Safety of Batracylin in Patients With Solid Tumors and Lymphomas
NCT00450502 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00450502 |
|---|---|
| Title | Safety of Batracylin in Patients With Solid Tumors and Lymphomas |
| Official title | A Phase I Study of Batracylin (NSC320846) in Subjects With Solid Tumors and Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Batracylin |
| Enrollment | 33 |
| Start date | Feb 24, 2007 |
| Primary completion | Apr 24, 2011 |
| Completion | Apr 24, 2011 |
| First posted | Mar 22, 2007 |
| Last update posted | Dec 5, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: